Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).
Maria C. Riesco Martinez
No relevant relationships to disclose
Scott R. Berry
Consultant or Advisory Role - Amgen; Roche; Sanofi
Honoraria - Amgen; Roche; Sanofi
Yoo-Joung Ko
Consultant or Advisory Role - Amgen; Roche; Sanofi
Nicole Mittmann
Consultant or Advisory Role - Amgen; Celgene
Kelly Lien
No relevant relationships to disclose
Shazia Hassan
No relevant relationships to disclose
Angie Giotis
No relevant relationships to disclose
Kelvin K. Chan
No relevant relationships to disclose